A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis
- Conditions
- Treatment of hyperphosphataemiaMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney disease
- Registration Number
- EUCTR2007-003885-16-PT
- Lead Sponsor
- Genzyme Europe BV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 400
Patients must meet the following criteria to be enrolled in the study:
1. Willing and able to provide written informed consent.
2. Men or women 18 years of age or older.
3. If currently on phosphate binder(s), willing to stop the phosphate binder and enter a 14-21 day Washout Period.
4. Have been, in the opinion of the Investigator, stable on a phosphate-controlled diet at Screening and be willing to avoid any intentional changes, such as fasting or dieting for the duration of the study.
5. Have the following central laboratory measurements:
• If not taking a phosphate binder at Screening, a serum phosphorous measurement =4.6 mg/dL (=1.49 mmol/L) and =5.5 mg/dL (=1.76 mmol/L) at Screening.
• If taking a phosphate binder at Screening, a serum phosphorous measurement =4.6 mg/dL (=1.49mmol/L) and =5.5 mg/dL (=1.76 mmol/L) after the 14-21 day Washout Period; at the Post-Washout Visit.
6. Willing and able to take the Investigational Product as a phosphate binder for the duration of the study.
7. Willing and able to maintain screening doses of lipid-lowering medication for the duration of the study, except for safety reasons.
8. Willing and able to maintain doses of medication for control of hyperparathyroidism from Screening through Week 12, except for safety reasons.
9. Willing and able to avoid antacids and phosphate binders containing aluminium, magnesium, calcium or lanthanum for the duration of the study unless prescribed as an evening calcium supplement.
10. Willing, if female and of childbearing potential (pre-menopausal and not surgically sterile), to use an effective contraceptive method throughout study, which includes barrier methods, hormones, or intrauterine device(s).
11. Expecting not to initiate dialysis or have a kidney transplant for the duration of this study.
12. Be considered compliant with phosphate binders (if applicable).
13. Has not participated in any other investigational drug studies within 30 days prior to enrolment.
14. Have a level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel.
15. Able to be contacted by phone or other remote means in order to be informed of Investigational Product dose changes.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Patients will be excluded from this study if they do not meet the specific inclusion criteria, or if they are/have:
1. Active dysphagia or swallowing disorder or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation.
2. Previous major gastrointestinal tract surgery.
3. In the opinion of the Investigator, active ethanol or drug abuser, excluding tobacco use.
4. Use of anti-arrhythmics for arrhythmias or anti-seizure medications for seizures.
5. At Screening, the following central laboratory measurements:
• Serum 25-hydroxyvitamin D <10 ng/mL (<25 nmol/L),
• Serum intact parathyroid hormone (iPTH) =600 pg/mL (=66 pmol/L), and
• Serum LDL >140 mg/dL (>3.59 mmol/L).
6. In the opinion of the Investigator, any clinically significant unstable medical condition, for example:
poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection.
7. Pregnant or breast-feeding.
8. Evidence of active malignancy except for basal cell carcinoma of the skin.
9. Unable to comply with the requirements of the study.
10. A known hypersensitivity to the Investigational Product or any of its constituents.
11. Any other condition, which in the opinion of the Investigator, would mean participation in the study would not be in the patient’s best interest.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method